ALIM:NSD-Alimera Sciences Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 4.90

Change

-0.13 (-2.58)%

Market Cap

USD 0.04B

Volume

0.04M

Avg Analyst Target

USD 13.25 (+170.41%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Alimera Sciences Inc (ALIM) Stock Analysis:
Based on the Alimera Sciences Inc stock forecasts from 2 analysts, the average analyst target price for Alimera Sciences Inc is USD 13.25 over the next 12 months. Alimera Sciences Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Alimera Sciences Inc is Neutral, which is based on 5 positive signals and 5 negative signals. At the last closing, Alimera Sciences Inc’s stock price was USD 4.90. Alimera Sciences Inc’s stock price has changed by -0.89 % over the past week, +0.85 % over the past month and +11.36 % over the last year.

About

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), wh ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-12-02 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MYL Mylan N.V

N/A

USD8.59B 30.73 11.86
NBIX Neurocrine Biosciences Inc

-0.15 (-0.19%)

USD8.04B 17.79 39.74
APHA Tilray, Inc

N/A

USD6.86B 60.60 454.68
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
TLRY Tilray Inc

+0.27 (+2.91%)

USD4.69B N/A N/A
CGC Canopy Growth Corporation

+0.42 (+4.23%)

USD4.22B N/A N/A
ITCI Intra-Cellular Therapies Inc

+0.08 (+0.21%)

USD3.33B N/A N/A
PCRX Pacira BioSciences Inc

+0.46 (+0.86%)

USD2.28B 39.33 17.58
DVAX Dynavax Technologies Corporati..

-0.41 (-2.71%)

USD1.93B N/A 98.57
IRWD Ironwood Pharmaceuticals Inc

+0.17 (+1.55%)

USD1.78B 3.37 7.24

ETFs Containing ALIM

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 16.11% 75% C 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.11% 75% C 65% D
Trailing 12 Months  
Capital Gain 11.36% 73% C 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.36% 73% C 54% F
Trailing 5 Years  
Capital Gain -69.47% 41% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -69.47% 41% F 10% F
Average Annual (5 Year Horizon)  
Capital Gain -12.96% 26% F 7% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.96% 26% F 6% F
Risk Return Profile  
Volatility (Standard Deviation) 45.96% 55% F 39% F
Risk Adjusted Return -28.20% 29% F 10% F
Market Capitalization 0.04B 12% F 9% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 12.81 65% D 61% D-
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -16.55 86% B 79% C+
EV/EBITDA 10.73 59% F 60% D-
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -1.23% 77% C+ 45% F
Return on Assets 2.66% 81% B- 69% D+
Debt to Equity Ratio -531.56% 95% A 98% A+
Technical Ratios  
Short Ratio 1.41 72% C- 69% D+
Short Percent 3.06% 66% D 46% F
Beta 1.67 25% F 20% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector